"Magic Bullets" at the center stage of immune therapy: a special issue on therapeutic antibodies.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Clinical MAPPs: a personalized healthcare-driven assay for the direct identification of potential T cell epitopes in patients.Frontiers in immunology · 2026
   Article
2. Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications.Signal transduction and targeted therapy · 2024
   Review
3. Constructing immune and prognostic features associated with ADCP in hepatocellular carcinoma and pan-cancer based on scRNA-seq and bulk RNA-seq.Frontiers in immunology · 2024
   Article
4. Establishing and validating an ADCP-related prognostic signature in pancreatic ductal adenocarcinoma.Aging · 2022
   Article
5. Current Advancements in Addressing Key Challenges of Therapeutic Antibody Design, Manufacture, and Formulation.Antibodies (Basel, Switzerland) · 2019
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as